HormonesComunicato stampa

Adding Testosterone to Estrogen Boosts Spine Bone Density in Postmenopausal Women

A small study finds women on estrogen plus testosterone gained lumbar spine bone density that estrogen alone did not deliver. Hip density stayed stable.

martedì 17 novembre 2026 0 visualizzazioni
Pubblicato in The Menopause Society
Article visualization: Adding Testosterone to Estrogen Boosts Spine Bone Density in Postmenopausal Women

Riepilogo

Bone loss after menopause is one of the biggest threats to women's long-term mobility and independence. Women can lose 10% to 20% of their bone density in the first five to seven years after menopause as estrogen falls. Estrogen therapy is a standard way to protect bone, but a small new study suggests adding testosterone may do more. Researchers followed 51 women for an average of 4.1 years, using DEXA scans to compare bone density during estrogen alone and during estrogen plus testosterone. Estrogen alone did not significantly raise T-scores at the lumbar spine, femoral neck or hip. Adding testosterone significantly increased lumbar spine T-scores, while hip and femoral neck scores held steady. The authors suggest testosterone works synergistically with estrogen on trabecular (spongy) bone. The findings are preliminary and come from a conference presentation, so they point toward further research rather than a change in practice.

Riepilogo Dettagliato

Menopause brings a steep drop in estrogen, and with it rapid bone loss. Women can lose 10% to 20% of their bone density in the first five to seven years afterward, raising the risk of osteopenia, osteoporosis and fractures. Fractures threaten mobility, independence and quality of life, which makes bone preservation a central healthspan goal for women.

Estrogen therapy is an established way to lower the risk of spine and hip fractures, alongside weight-bearing and resistance exercise and adequate calcium and vitamin D. This new study asked whether adding testosterone could build on estrogen's benefits. It followed 51 women for an average of 4.1 years. They received estrogen for a mean of 3.5 years and estrogen plus testosterone for 3.1 years. DEXA scans measured bone density at baseline, after at least one year of estrogen alone, and after at least one year of the combination.

Estrogen alone produced no significant T-score increases at the lumbar spine, femoral neck or hip. Adding testosterone significantly raised lumbar spine T-scores, while femoral neck and hip scores remained stable in both periods. The researchers interpret this as a possible synergy between the two hormones on trabecular bone, which is abundant in the spine and turns over quickly.

The practical message is cautious. Women and clinicians interested in bone health should continue to rely on proven foundations: resistance and weight-bearing exercise, calcium, vitamin D, and, when appropriate, standard hormone therapy. Testosterone for bone is not an established indication, and decisions belong in individualized care with a knowledgeable clinician.

The caveats matter. The study is small, appears to use a sequential design without a randomized control group, and was presented at a meeting rather than published in a peer-reviewed journal. Fracture outcomes were not reported, and long-term safety of testosterone in women was not addressed. Changes over time may also reflect longer total treatment. Larger randomized trials are needed.

Risultati Principali

  • Estrogen alone did not significantly raise T-scores at the lumbar spine, femoral neck or hip in 51 women.
  • Adding testosterone significantly increased lumbar spine T-scores after at least one year.
  • Femoral neck and hip T-scores stayed stable during both estrogen alone and combined therapy.
  • Women can lose 10% to 20% of bone density within five to seven years after menopause.
  • Authors propose testosterone synergizes with estrogen on trabecular bone; larger controlled trials are still needed.

Metodologia

This is a press release on a small observational study (51 women, average 4.1-year follow-up) to be presented at The Menopause Society annual meeting. The source is a credible professional society, but the data are not yet peer-reviewed. Each woman appears to serve as her own comparison across treatment periods.

Limitazioni dello Studio

The study is small, lacks a randomized control group, and reports bone density rather than fracture outcomes. Treatment durations differed and safety data on testosterone in women are not described. Verify details in the full abstract or eventual publication, including doses, formulations and participant characteristics.

Ti è piaciuto questo riepilogo?

Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.

Inserisci la tua email per iscriverti: